Wecome Pharmaceutical Co Ltd (300878) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.001x

Based on the latest financial reports, Wecome Pharmaceutical Co Ltd (300878) has a cash flow conversion efficiency ratio of -0.001x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-1.42 Million ≈ $-208.32K USD) by net assets (CN¥1.03 Billion ≈ $150.67 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Wecome Pharmaceutical Co Ltd (300878) defensive interval to measure how many days the company can operate on defensive assets alone.

Wecome Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2013–2024)

This chart illustrates how Wecome Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Wecome Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Wecome Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Beijing Advanced Digital Technology Co Ltd SHE:300541	0.139x
Fedbank Financial Services Limited NSE:FEDFINA	0.039x
People & Technology Inc KQ:137400	0.023x
Solid Biosciences LLC NASDAQ:SLDB	-0.126x
Redwood Trust Inc NYSE:RWT	-4.710x
Complete Logistic Services Bhd KLSE:5136	0.029x
Algoma Central Corporation TO:ALC	0.043x
Shanghai Hollywave Electronic System Co. Ltd. A SHG:688682	-0.012x

Annual Cash Flow Conversion Efficiency for Wecome Pharmaceutical Co Ltd (2013–2024)

The table below shows the annual cash flow conversion efficiency of Wecome Pharmaceutical Co Ltd from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Wecome Pharmaceutical Co Ltd.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	CN¥1.17 Billion ≈ $171.77 Million	CN¥-27.17 Million ≈ $-3.98 Million	-0.023x	-155.89%
2023-12-31	CN¥1.41 Billion ≈ $205.95 Million	CN¥58.29 Million ≈ $8.53 Million	0.041x	-60.11%
2022-12-31	CN¥1.41 Billion ≈ $206.55 Million	CN¥146.57 Million ≈ $21.45 Million	0.104x	+315.97%
2021-12-31	CN¥1.41 Billion ≈ $206.18 Million	CN¥-67.74 Million ≈ $-9.91 Million	-0.048x	-255.47%
2020-12-31	CN¥1.38 Billion ≈ $202.58 Million	CN¥42.81 Million ≈ $6.26 Million	0.031x	-85.74%
2019-12-31	CN¥519.84 Million ≈ $76.07 Million	CN¥112.76 Million ≈ $16.50 Million	0.217x	-19.08%
2018-12-31	CN¥393.83 Million ≈ $57.63 Million	CN¥105.57 Million ≈ $15.45 Million	0.268x	+182.87%
2017-12-31	CN¥306.05 Million ≈ $44.79 Million	CN¥29.00 Million ≈ $4.24 Million	0.095x	-80.04%
2016-12-31	CN¥210.90 Million ≈ $30.86 Million	CN¥100.15 Million ≈ $14.66 Million	0.475x	+108.41%
2015-12-31	CN¥130.04 Million ≈ $19.03 Million	CN¥29.63 Million ≈ $4.34 Million	0.228x	-61.26%
2014-12-31	CN¥78.22 Million ≈ $11.45 Million	CN¥46.01 Million ≈ $6.73 Million	0.588x	-22.24%
2013-12-31	CN¥34.35 Million ≈ $5.03 Million	CN¥25.98 Million ≈ $3.80 Million	0.756x	--

About Wecome Pharmaceutical Co Ltd

SHE:300878 China Biotechnology

Market Cap

$646.21 Million

CN¥4.42 Billion CNY

Market Cap Rank

#11129 Global

#3151 in China

Share Price

CN¥30.50

Change (1 day)

-2.27%

52-Week Range

CN¥15.29 - CN¥36.20

All Time High

CN¥52.21